P

Puma Biotechnology

D
PBYI
USD
-0.02
(-0.6547%)
Market Closed
9,738.00
Volume
0.31
EPS
-
Div Yield
15.368
P/E
148,856,804.31
Market Cap
Today
0.4967%
1 Week
6.491%
1 Month
14.098%
6 Months
-35.970%
12 Months
3.938%
Year To Date
-30.069%
All Time
0%

Title:
Puma Biotechnology

Sector:
Healthcare
Industry:
Biotechnology
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
Do you need help or have a question?